EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway

Lixue Cao, Yanzhen Chen, Yingqi Liu, Changnian Yang iD, Zhentao Zhang, Yongqing Lin, Yiyuan Wang iD, Siman Chen, Fei Yu iD, Haiyan Ye iD, Shanshan Wu iD

Cancer Medicine · 2026

DOI: 10.1002/cam4.72309 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Lixue Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, G…. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Carcinoma, Ovarian Epithelial, Phosphatidylinositol 3-Kinases, Ovarian Neoplasms. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation, Guangdong Province Science and Technology Innovation Strategy Special Fund for College Students' Scientific and Technological Innovation Cultivation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Epithelial ovarian cancer (EOC) frequently disseminates within the lipid‐rich peritoneal cavity, where tumor progression is accompanied by metabolic adaptations involving lipid utilization and mitochondrial function. Although these metabolic alterations are increasingly recognized as important features of EOC progression and peritoneal metastasis, the molecular factors linking mitochondrial–lipid metabolic remodeling with aggressive tumor behavior remain incompletely characterized. We therefore integrated mitochondrial‐ and lipid metabolism‐related transcriptomic analyses to identify candidate regulators and further investigated the clinical and biological features associated with CDS2.

Results

Seven key genes associated with mitochondrial and lipid metabolism were identified in EOC through comprehensive bioinformatic analyses and were used to construct the MALRS prognostic model. Further integration of FIGO stage, histologic grade, and MALRS scores yielded a nomogram whose calibration plots showed good agreement between predicted and observed 1‐, 3‐, and 5‐year survival probabilities. Subsequent screening of these candidate genes in chemotherapy‐resistant datasets identified CDP‐diacylglycerol synthase 2 (CDS2) as the most consistently upregulated candidate gene. Clinical validation confirmed that CDS2 was significantly overexpressed in tumor tissues and was associated with advanced disease stage, and survival analysis showed that higher CDS2 expression was associated with shorter progression‐free survival (PFS) in stage III/IV patients. Functional characterization demonstrated that CDS2 overexpression promoted both lipid droplet accumulation and migratory capacity in ovarian cancer cells. Pathway analysis identified significant enrichment of PI3K/AKT signaling, and experimental validation confirmed CDS2‐mediated hyperactivation of PI3K/AKT phosphorylation. Computational immune‐deconvolution analyses further identified exploratory associations between CDS2 expression, estimated T‐cell abundance, and immune‐checkpoint transcripts.

Conclusion

CDS2 is a lipid metabolism‐associated candidate biomarker linked to aggressive clinicopathological features in EOC. Our findings associate CDS2 with disease progression, PI3K/AKT‐related signaling, and immune‐related transcriptomic features, supporting its further evaluation as a candidate prognostic marker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-aktCarcinoma, Ovarian EpithelialPhosphatidylinositol 3-KinasesOvarian NeoplasmsHumansFemaleDisease ProgressionSignal TransductionPrognosisGene Expression Regulation, NeoplasticLipid MetabolismBiomarkers, TumorCell Line, Tumor

Stichwörter der Autor:innen

CDS2EOCPI3K/AKT signaling pathwayimmune microenvironmentlipid metabolism

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Medical Research Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China.
  • Department of Gynecology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, Guangzhou, Guangdong, China.
  • The First School of Clinical Medicine, Guangdong Medical University, Zhanjiang, Guangdong, China.
  • School of Obstetrics and Pediatrics, Guangdong Medical University, Zhanjiang, Guangdong, China.
  • Department of Biology, School of Basic Medical Sciences, Guangdong Medical University, Zhanjiang, Guangdong, China.

ORCID-Profile: Changnian Yang, Yiyuan Wang, Fei Yu, Haiyan Ye, Shanshan Wu

Förderung

  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Guangdong Province Science and Technology Innovation Strategy Special Fund for College Students' Scientific and Technological Innovation Cultivation
  • 2024 Undergraduate Innovation and Entrepreneurship Education Base Project of Guangdong Medical University
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Cao, L., Chen, Y., Liu, Y., Yang, C., Zhang, Z., Lin, Y., Wang, Y., Chen, S., Yu, F., Ye, H., & Wu, S. (2026). CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway. Cancer Medicine. https://doi.org/10.1002/cam4.72309

Vancouver

Cao L, Chen Y, Liu Y, Yang C, Zhang Z, Lin Y, et al. CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway. Cancer Medicine. 2026. doi:10.1002/cam4.72309

BibTeX
@article{Cao2026,
  author = {Cao, Lixue and Chen, Yanzhen and Liu, Yingqi and Yang, Changnian and Zhang, Zhentao and Lin, Yongqing and Wang, Yiyuan and Chen, Siman and Yu, Fei and Ye, Haiyan and Wu, Shanshan},
  title = {CDS2 Drives Tumor Progression in Epithelial Ovarian Cancer via the PI3K/AKT Pathway},
  journal = {Cancer Medicine},
  year = {2026},
  doi = {10.1002/cam4.72309}
}
Kostenlos starten →